Diros develops and markets a portfolio of RF generators, cannulae and unique tined probe technology that delivers RF energy through minimally invasive probes that heat nervous tissue to prevent the transfer of pain signals

robina-weermeijer-IHfOpAzzjHM-unsplash

Avanos to acquire Diros Technology. (Credit: Robina Weermeijer on Unsplash)

US-based medical device maker Avanos Medical has agreed to acquire Diros Technology, a manufacturer of radiofrequency (RF) products for neurosurgery and pain management.

Based in Toronto, Canada, Diros develops and markets a portfolio of RF generators, cannulae and unique tined probe technology under its Trident brand.

The company’s ablation products deliver RF energy through precisely placed, minimally invasive probes that heat nervous tissue to prevent the transfer of pain signals.

With the acquisition, Avanos will add Diros’ RF Trident technology to further enhance its pain management treatment options.

Also, the RF Trident technology will complement Avanos’ premium COOLIEF Cooled Radiofrequency product offering.

The transaction is expected to be completed in the third quarter of this year, subject to certain customary closing conditions.

Avanos intends to finance the acquisition through a combination of available cash on hand, and funds from its existing credit facility.

Avanos CEO Joe Woody said: “The acquisition of Diros Technology strengthens Avanos’ leadership position in RF technology by providing a full range of high-quality, differentiated pain management products.

“We expect our enhanced portfolio will offer significant opportunities to deliver non-opioid-based, minimally invasive treatments to patients throughout the world.

“With this comprehensive suite of RF offerings, we believe Avanos is poised for future growth across all major sites of patient care: hospitals, ambulatory surgery centres and physician’s offices.”

Earlier this month, US-based medical device company SunMed signed an agreement to acquire Avanos Medical’s respiratory health (RH) business.

The acquisition includes all the assets related to Avanos’ Ballard, Microcuff and endOclear brands, along with research and development experts who support these brands.